Effectiveness and safety of a third-line rescue treatment for acute severe ulcerative colitis refractory to infliximab or ciclosporin (REASUC study).

Fecha de publicación: 06/03/2024 Fecha Ahead of Print: 01/03/2024

Autores de IIS La Fe

• Mariam Aguas Peris

  Autor

• Javier Pérez Gisbert

  Autor

• Natalia Chaparro Aguilera

  Autor

Participantes ajenos a IIS La Fe

• Garcia, Maria Jose
• Riestra, Sabino
• Amiot, Aurelien
• Julsgaard, Mette
• Garcia de la Filia, Irene
• Calafat, Margalida
• de la Pena, Luisa
• Roig, Cristina
• Caballol, Berta
• Casanova, Maria Jose
• Farkas, Klaudia
• Boysen, Trine
• Bujanda, Luis
• Cuaran, Camila
• Dobru, Daniela
• Fousekis, Fotios
• Gargallo-Puyuelo, Carla Jerusalen
• Savarino, Edoardo
• Calvet, Xavier
• Huguet, Jose Maria
• Kupcinskas, Limas
• Lopez-Cardona, Julia
• Raine, Tim
• van Oostrom, Joep

Grupos

• Enfermedad Inflamatoria Intestinal

  

  Leader

  Pilar Nos Mateu

Abstract

BACKGROUND: The advent of new therapeutic agents and the improvement of supporting care might change the management of acute severe ulcerative colitis (ASUC) and avoid colectomy. AIMS: To evaluate the colectomy-free survival and safety of a third-line treatment in patients with ASUC refractory to intravenous steroids and who failed either infliximab or ciclosporin. METHODS: Multicentre retrospective cohortstudy of patients with ASUC refractory to intravenous steroids who had failed infliximab or ciclosporin and received a third-line treatment during the same hospitalisation. Patients who stopped second-line treatment due to disease activity or adverse events (AEs) were eligible. We assessed short-term colectomy-free survival by logistic regression analysis. Kaplan-Meier curves and Cox regression models were used for long-term assessment. RESULTS: Among 78 patients, 32 received infliximab and 46 ciclosporin as second-line rescue treatment. Third-line treatment was infliximab in 45 (58%), ciclosporin in 17 (22%), tofacitinib in 13 (17%) and ustekinumab in 3 (3.8%). Colectomy was performed in 29 patients (37%) during follow-up (median 21weeks). Of the 78 patients, 32 and 18 were in clinical remission at, respectively, 12 and 52weeks. At the last visit, 25 patients were still on third-line rescue treatment, while 12 had stopped it due to clinical remission. AEs were reported in 26 (33%) patients. Two patients died (2.6%), including one following colectomy. CONCLUSION: Third-line rescue treatment avoided colectomy in over half of the patients with ASUC and may be considered a therapeutic strategy.

© 2024 John Wiley & Sons Ltd.

Keywords

• INFLAMMATORY-BOWEL-DISEASE; MAINTENANCE THERAPY; HOSPITALIZED-PATIENTS; TOFACITINIB; INDUCTION; USTEKINUMAB; EFFICACY; STRATEGIES; GUIDELINES; MANAGEMENT